Gina Chapman, CARGO Therapeutics president and CEO

CAR­GO Ther­a­peu­tics eyes one of 2023's largest IPOs in a dull year for list­ings

Biotech start­up CAR­GO Ther­a­peu­tics looks to land one of the biggest Nas­daq list­ings in a bar­ren year for life sci­ences ini­tial pub­lic of­fer­ings.

If the blood can­cer cell ther­a­py mak­er can gar­ner enough in­vestor in­trigue for an IPO at its pro­posed mid­point price of $16 per share, then its Wall Street de­but would be near­ly equal in size to Apogee Ther­a­peu­tics’ $300 mil­lion launch in Ju­ly but be­low Rayze­Bio’s $311 mil­lion in Sep­tem­ber and Ace­lyrin’s $540 mil­lion in May.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.